Please select the option that best describes you:
What systemic therapy would you offer to a postmenopausal patient with an unresectable local recurrence of HER2+/ER weakly + IDC?
In a patient with who had undergone neoadjuvant TCH-P, lumpectomy, and RT and is currently on AI, pertuzumab, and trastuzumab, how do you think about systemic therapy options?
Answer from: Medical Oncologist at Academic Institution
For local recurrences, in general I think about 4 situations based on whether it is resectable or not and whether it is during or soon after adjuvant therapy or not. In this case, we have an unresectable local recurrence during adjuvant therapy within a year after surgery, since it is during a...
Sign in or Register to read more